What is she best known for?
The fields of study she is best known for:
- Cancer
- Internal medicine
- Gene
Her main research concerns Breast cancer, Cancer, Internal medicine, Oncology and Ovarian cancer.
Judy Garber interconnects Germline mutation, Gynecology, Cancer research and Risk factor in the investigation of issues within Breast cancer.
Her Cancer research integrates issues from Odds ratio, Bioinformatics, Genetic testing and Medical genetics.
Her research investigates the connection between Internal medicine and topics such as Gene mutation that intersect with issues in Estrogen receptor.
Her Oncology study integrates concerns from other disciplines, such as BRCA2 Protein, Li–Fraumeni syndrome, Pathology, Tamoxifen and Triple-negative breast cancer.
Her research in Ovarian cancer focuses on subjects like Fallopian tube, which are connected to Serous Tubal Intraepithelial Carcinoma and Serous carcinoma.
Her most cited work include:
- The human mutator gene homolog MSH2 and its association with hereditary nonpolyposis colon cancer. (2569 citations)
- Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial (1872 citations)
- Mutational Processes Molding the Genomes of 21 Breast Cancers (1329 citations)
What are the main themes of her work throughout her whole career to date?
Judy Garber mainly focuses on Breast cancer, Internal medicine, Oncology, Cancer and Genetic testing.
Her biological study spans a wide range of topics, including Germline mutation, Cancer research, Gynecology, Ovarian cancer and Family history.
Her Internal medicine research is multidisciplinary, incorporating elements of Li–Fraumeni syndrome and Pathology.
Her Oncology research incorporates elements of Chemotherapy, Phases of clinical research, Germline, Tamoxifen and Triple-negative breast cancer.
Her Cancer research is multidisciplinary, incorporating perspectives in Mutation and Bioinformatics.
The various areas that Judy Garber examines in her Genetic testing study include Genetic counseling and Family medicine.
She most often published in these fields:
- Breast cancer (39.86%)
- Internal medicine (38.22%)
- Oncology (32.47%)
What were the highlights of her more recent work (between 2018-2021)?
- Breast cancer (39.86%)
- Internal medicine (38.22%)
- Oncology (32.47%)
In recent papers she was focusing on the following fields of study:
Judy Garber mainly investigates Breast cancer, Internal medicine, Oncology, Cancer and Germline.
Her research in Breast cancer intersects with topics in Placebo and Cancer research.
Her Internal medicine study frequently links to adjacent areas such as Polygenic risk score.
Her Oncology research incorporates themes from Odds ratio, Pancreatic cancer, CHEK2, PALB2 and Ovarian cancer.
Her Cancer research includes elements of Phenotype, Disease and Li–Fraumeni syndrome.
Her work carried out in the field of Genetic testing brings together such families of science as Genetic counseling and Family medicine.
Between 2018 and 2021, her most popular works were:
- NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 1.2020. (153 citations)
- Cancer Risks Associated With Germline PALB2 Pathogenic Variants: An International Study of 524 Families (100 citations)
- Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses (53 citations)
In her most recent research, the most cited papers focused on:
- Cancer
- Internal medicine
- Gene
Her primary areas of study are Breast cancer, Internal medicine, Oncology, Cancer and Cancer research.
Her Breast cancer study combines topics from a wide range of disciplines, such as CHEK2, Germline and Immunohistochemistry.
Her studies examine the connections between Internal medicine and genetics, as well as such issues in Human genetics, with regards to Heterozygote advantage and Missense mutation.
Her Oncology research incorporates themes from Odds ratio, Cohort study, Ovarian cancer, Penetrance and Genetic testing.
The study incorporates disciplines such as Phenotype, Disease, Clinical genomics, Research center and Subject in addition to Cancer.
Her Cancer research study integrates concerns from other disciplines, such as Olaparib, PARP inhibitor and Estrogen.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
